News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
129,334 Results
Type
Article (4292)
Company Profile (88)
Press Release (124954)
Section
Business (42054)
Career Advice (208)
Deals (6158)
Drug Delivery (13)
Drug Development (17411)
Employer Resources (18)
FDA (1485)
Job Trends (2777)
News (66166)
Policy (3644)
Tag
2024 BioCapital Digital (2)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (5)
2024 Biotech Beach Digital (7)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (6)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (1)
2025 Lone Star Bio Digital (1)
2026 Biotech Bay Standard (1)
Academia (291)
Adcomms (1)
Allergies (16)
Alliances (11441)
ALS (28)
Alzheimer's disease (324)
Antibody-drug conjugate (ADC) (26)
Approvals (1497)
Artificial intelligence (46)
Autoimmune disease (8)
Automation (3)
Bankruptcy (38)
Best Places to Work (2250)
BIOSECURE Act (13)
Biosimilars (6)
Biotechnology (85)
Bladder cancer (19)
Brain cancer (6)
Breast cancer (62)
Cancer (516)
Cardiovascular disease (15)
Career advice (196)
Career pathing (4)
CAR-T (54)
Cell therapy (163)
Cervical cancer (6)
Clinical research (14076)
Collaboration (240)
Compensation (105)
Complete response letters (2)
COVID-19 (428)
CRISPR (7)
C-suite (97)
Cystic fibrosis (26)
Data (553)
Depression (7)
Diabetes (47)
Diagnostics (693)
Digital health (1)
Diversity, equity & inclusion (8)
Drug discovery (42)
Drug pricing (5)
Drug shortages (2)
Duchenne muscular dystrophy (20)
Earnings (12479)
Editorial (4)
Employer resources (18)
Events (24585)
Executive appointments (248)
FDA (1706)
Featured Employer (13)
Frontotemporal dementia (5)
Funding (210)
Gene editing (20)
Generative AI (4)
Gene therapy (78)
GLP-1 (108)
Government (341)
Guidances (8)
Healthcare (1528)
Huntington's disease (6)
IgA nephropathy (7)
Immunology and inflammation (23)
Indications (9)
Infectious disease (454)
Inflammatory bowel disease (51)
Inflation Reduction Act (1)
Influenza (16)
Intellectual property (33)
Interviews (17)
IPO (2933)
IRA (4)
Job creations (665)
Job search strategy (184)
Kidney cancer (1)
Labor market (7)
Layoffs (37)
Legal (638)
Liver cancer (12)
Lung cancer (40)
Lymphoma (47)
Management (4)
Manufacturing (76)
MASH (10)
Medical device (397)
Medtech (397)
Mergers & acquisitions (3409)
Metabolic disorders (110)
Multiple sclerosis (23)
NASH (1)
Neurodegenerative disease (16)
Neuropsychiatric disorders (3)
Neuroscience (445)
NextGen: Class of 2025 (857)
Non-profit (273)
Northern California (783)
Now hiring (4)
Obesity (56)
Opinion (37)
Ovarian cancer (29)
Pain (19)
Pancreatic cancer (19)
Parkinson's disease (37)
Partnered (4)
Patents (51)
Patient recruitment (26)
Peanut (12)
People (16392)
Pharmaceutical (8)
Phase I (5581)
Phase II (6723)
Phase III (3449)
Pipeline (298)
Podcasts (2)
Policy (23)
Postmarket research (209)
Preclinical (2389)
Press Release (51)
Prostate cancer (18)
Psychedelics (2)
Radiopharmaceuticals (46)
Rare diseases (64)
Real estate (1442)
Recruiting (10)
Regulatory (2948)
Reports (13)
Research institute (297)
Resumes & cover letters (20)
RSV (4)
Schizophrenia (12)
Series A (38)
Series B (28)
Service/supplier (2)
Sickle cell disease (11)
Southern California (715)
Special edition (1)
Spinal muscular atrophy (36)
Sponsored (4)
Startups (983)
State (1)
Stomach cancer (2)
Supply chain (14)
Tariffs (3)
The Weekly (2)
United States (5890)
Vaccines (74)
Venture capitalists (7)
Webinars (6)
Weight loss (20)
Women's health (4)
Worklife (2)
Date
Today (35)
Last 7 days (176)
Last 30 days (688)
Last 365 days (8854)
2025 (2252)
2024 (9143)
2023 (9881)
2022 (11997)
2021 (12647)
2020 (9853)
2019 (6675)
2018 (5277)
2017 (6074)
2016 (5592)
2015 (6439)
2014 (4922)
2013 (4060)
2012 (4397)
2011 (4870)
2010 (4514)
Location
Africa (137)
Alabama (28)
Alaska (1)
Arizona (25)
Arkansas (2)
Asia (8456)
Australia (1992)
California (1793)
Canada (516)
China (103)
Colorado (29)
Connecticut (64)
Delaware (22)
Europe (18428)
Florida (164)
Georgia (25)
Idaho (10)
Illinois (121)
India (3)
Indiana (91)
Iowa (1)
Japan (32)
Kansas (11)
Kentucky (2)
Louisiana (1)
Maine (2)
Maryland (207)
Massachusetts (1306)
Michigan (66)
Minnesota (93)
Missouri (7)
Montana (8)
Nebraska (2)
Nevada (4)
New Hampshire (5)
New Jersey (394)
New Mexico (6)
New York (428)
North Carolina (260)
North Dakota (3)
Northern California (783)
Ohio (37)
Oklahoma (5)
Oregon (4)
Pennsylvania (355)
Puerto Rico (3)
Rhode Island (4)
South America (198)
South Carolina (1)
Southern California (715)
Tennessee (15)
Texas (206)
Utah (18)
Virginia (10)
Washington D.C. (7)
Washington State (308)
Wisconsin (5)
129,334 Results for "iliad biotechnologies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay
December 24, 2024
·
3 min read
Business
ILiAD Biotechnologies to Participate in Upcoming Investor Conferences
October 1, 2024
·
1 min read
Drug Development
ILiAD Biotechnologies Reports Positive Topline Interim Results from Phase 2b School-Age Trial of BPZE1 Pertussis Vaccine
ILiAD Biotechnologies, LLC (ILiAD) reported today that BPZE1, the most advanced next generation pertussis vaccine, demonstrated positive topline interim results in the SUPER (Stand Up to Pertussis) school-age trial conducted in 366 participants in the United Kingdom, Australia and Costa Rica.
May 28, 2024
·
6 min read
Drug Development
ILiAD Biotechnologies Announces Planned Collaboration with Emmes Group, a New Mountain Capital Portfolio Company, to Conduct Upcoming Phase III Clinical Trials of BPZE1, the Leading Next-Generation Pertussis Vaccine
ILiAD Biotechnologies, LLC today announced the selection of Emmes Group, a global contract research and technology organization, to conduct upcoming Phase III studies of its lead pertussis vaccine candidate, BPZE1. ILiAD and Emmes Group are currently working to finalize the definitive agreement.
June 24, 2024
·
4 min read
Press Releases
UK MHRA Grants Innovation Passport Designation to ILiAD Biotechnologies BPZE1 Next Generation Intranasal Pertussis Vaccine
December 4, 2024
·
5 min read
Press Releases
ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting
January 27, 2025
·
5 min read
ILiAD Biotechnologies Announces Presentation at the 2023 World Vaccine Congress in Barcelona
ILiAD Biotechnologies, LLC (ILiAD), a vaccine company utilizing its B-Tech technology to develop novel vaccines against infectious diseases, today announced Chief Medical Officer Stephanie Noviello, MD, MPH, will present data on its pertussis vaccine, BPZE1, at the World Vaccine Congress Europe in Barcelona, Spain (October 17 – 19, 2023).
October 18, 2023
·
4 min read
ILiAD Biotechnologies Announces Presentation at the World Vaccine Congress
ILiAD Biotechnologies, LLC (ILiAD), a vaccine company utilizing its B-Tech™ technology to develop novel vaccines against infectious diseases, today announced that Chief Medical Officer Stephanie Noviello, MD, MPH, will present information regarding its pertussis vaccine, BPZE1, at the World Vaccine Congress in Washington, DC (April 3 – 6, 2023).
April 5, 2023
·
4 min read
Drug Development
ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phase 2b Human Challenge Study of BPZE1 Vaccine
ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most advanced next generation pertussis vaccine announces positive primary data outcomes in the CHAMPION-1 clinical trial conducted at University Hospital Southampton (UK) and University of Oxford (UK).
September 5, 2023
·
10 min read
Drug Development
ILiAD Biotechnologies Announces Publication of BPZE1 Adult Phase 2b Clinical Results in The Lancet
ILiAD Biotechnologies, LLC (ILiAD), a vaccine company utilizing its B-Tech technology to develop novel vaccines against infectious diseases, today announced a peer-reviewed publication in The Lancet.
March 10, 2023
·
5 min read
1 of 12,934
Next
